Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors : a systematic review and meta-analysis
BACKGROUND: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately.
METHODS: The literature search was performed by two independent reviewers following the previous protocol (PROSPERO 2014:CRD42014014147). A random-effects model and a fixed-effect model were used according to the characteristics of the included studies. Peto odds ratios with 95%CI were computed.
RESULTS: Overall, 4.78% of patients developed arterial occlusive events with new generation TKIs compared with 0.96% with imatinib. Ponatinib (ORPETO:3.26; 95%CI:1.12 to 9.50), nilotinib (ORPETO: 3.69; 95%CI:2.29 to 5.95) and dasatinib (ORPETO:3.32; 95%CI:1.37 to 8.01) are all associated with a higher risk of arterial occlusive events than imatinib. Venous occlusive events occur in 0.72% of patients treated with new generation TKIs and in 0.27% of imatinib-treated patients. Overall, a trend toward an increase of the rate of venous occlusive events with new-generation TKIs (ORPETO:2.17; 95%CI:0.90 to 5.25) was highlighted but stratifications by treatment gave nonsignificant results.
CONCLUSIONS: Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2017 |
---|---|
Erschienen: |
2017 |
Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
---|---|
Enthalten in: |
Expert opinion on drug safety - 16(2017), 1 vom: 31. Jan., Seite 5-12 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Haguet, Hélène [VerfasserIn] |
---|
Anmerkungen: |
Date Completed 10.03.2017 Date Revised 14.01.2022 published: Print-Electronic Citation Status MEDLINE |
---|
Förderinstitution / Projekttitel: |
|
---|
PPN (Katalog-ID): |
NLM266243541 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM266243541 | ||
003 | DE-627 | ||
005 | 20231224214052.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2017 xx |||||o 00| ||eng c | ||
028 | 5 | 2 | |a pubmed24n0887.xml |
035 | |a (DE-627)NLM266243541 | ||
035 | |a (NLM)27852118 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Haguet, Hélène |e verfasserin |4 aut | |
245 | 1 | 0 | |a Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors |b a systematic review and meta-analysis |
264 | 1 | |c 2017 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 10.03.2017 | ||
500 | |a Date Revised 14.01.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: A previous meta-analysis demonstrated that 3 of the new-generation BCR-ABL tyrosine kinase inhibitors (TKIs) (dasatinib, nilotinib and ponatinib) are associated with an increased risk of vascular occlusive events in patients with Ph+ chronic myeloid leukemia compared with imatinib. This meta-analysis of randomized controlled trials aims at assessing these risks separately | ||
520 | |a METHODS: The literature search was performed by two independent reviewers following the previous protocol (PROSPERO 2014:CRD42014014147). A random-effects model and a fixed-effect model were used according to the characteristics of the included studies. Peto odds ratios with 95%CI were computed | ||
520 | |a RESULTS: Overall, 4.78% of patients developed arterial occlusive events with new generation TKIs compared with 0.96% with imatinib. Ponatinib (ORPETO:3.26; 95%CI:1.12 to 9.50), nilotinib (ORPETO: 3.69; 95%CI:2.29 to 5.95) and dasatinib (ORPETO:3.32; 95%CI:1.37 to 8.01) are all associated with a higher risk of arterial occlusive events than imatinib. Venous occlusive events occur in 0.72% of patients treated with new generation TKIs and in 0.27% of imatinib-treated patients. Overall, a trend toward an increase of the rate of venous occlusive events with new-generation TKIs (ORPETO:2.17; 95%CI:0.90 to 5.25) was highlighted but stratifications by treatment gave nonsignificant results | ||
520 | |a CONCLUSIONS: Vascular occlusive events associated with new-generation BCR-ABL TKIs are driven by arterial occlusive events | ||
650 | 4 | |a Comparative Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Review | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Arterial occlusive disease | |
650 | 4 | |a BCR-ABL positive | |
650 | 4 | |a chronic | |
650 | 4 | |a leukemia | |
650 | 4 | |a meta-analysis | |
650 | 4 | |a myelogenous | |
650 | 4 | |a protein kinase inhibitors | |
650 | 4 | |a venous thrombosis | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Imidazoles |2 NLM | |
650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
650 | 7 | |a Pyridazines |2 NLM | |
650 | 7 | |a Pyrimidines |2 NLM | |
650 | 7 | |a ponatinib |2 NLM | |
650 | 7 | |a 4340891KFS |2 NLM | |
650 | 7 | |a Imatinib Mesylate |2 NLM | |
650 | 7 | |a 8A1O1M485B |2 NLM | |
650 | 7 | |a Fusion Proteins, bcr-abl |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a nilotinib |2 NLM | |
650 | 7 | |a F41401512X |2 NLM | |
650 | 7 | |a Dasatinib |2 NLM | |
650 | 7 | |a RBZ1571X5H |2 NLM | |
700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
700 | 1 | |a Chatelain, Christian |e verfasserin |4 aut | |
700 | 1 | |a Graux, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Expert opinion on drug safety |d 2002 |g 16(2017), 1 vom: 31. Jan., Seite 5-12 |w (DE-627)NLM126588422 |x 1744-764X |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2017 |g number:1 |g day:31 |g month:01 |g pages:5-12 |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 16 |j 2017 |e 1 |b 31 |c 01 |h 5-12 |